Tag: REV-004

May 25, 2017

Revive Therapeutics Releases Financial Report

Revive Therapeutics announced the results for the three and nine months ended March 31, 2017.
March 29, 2017

Revive Therapeutics Gives Corporate Update

Revive Therapeutics (TSXV:RVV, OTCQB:RVVTF) updated the status of its clinical study for REV-004 Bucillamine in cystinuria and warrant exercise.